Diabetes and CVD module 4: Optimising cardiovascular risk reduction in diabetes

Released20 September 2018     Expires: 20 September 2020      Programme: Diabetes and CVD 0.5 CPD/CME credit, 0.5 hours

Sponsorship Statement: AstraZeneca provided an unsolicited arms-length educational grant to fund the production of this supplement. AstraZeneca had no editorial input into the content other than a review for technical accuracy.

Designed to give healthcare professionals an understanding of the scope of the problem of management of cardiovascular disease in the patient with diabetes.

Learning objectives

After completing this module, participants should be better able to understand:

  • Although good glycaemic control in diabetes remains the optimal way to reduce microvascular complications, cardiovascular risk reduction is a priority in the management of type 2 diabetes
  • Lifestyle intervention may not provide cardiovascular (CV) benefit in those with diabetes, although, as it improves overall wellbeing, it should still be advocated
  • Good blood pressure control, however achieved, is essential
  • People with diabetes should receive a statin unless there is a compelling reason not to
  • If cholesterol targets are not achieved on statin alone, or a patient is intolerant, ezetimibe may provide additional benefit in those with diabetes and previous CV event
  • There is no role in primary prevention for antithrombotics, although aspirin and/or clopidogrel should be used in secondary prevention
  • Newer biological agents may have a role in the very high risk, however, the cost-effectiveness of such strategies has not been evaluated


W David Strain, Clinical Senior Lecturer and Honorary Consultant, University of Exeter Medical School, Institute of Biomedical and Clinical Science, Department of Diabetes and Vascular Research, Royal Devon & Exeter Hospital

With thanks to Dr Sam Pearson, Specialist Registrar in Diabetes and Endocrinology, St James’s University Hospital, Leeds, for assistance on the self-assessment aspect of the programme.


0.5 CPD/CME credit, 0.5 hours
BJC Learning has assigned half an hour of CPD/CME credit to this module

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

32 thoughts on “Diabetes and CVD module 4: Optimising cardiovascular risk reduction in diabetes”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.